Sara Medek, MD
Head and Neck Cancer
Phase 3
Protocol NANORAY-312
This study looks at how effective a new treatment, NBTXR3 combined with radiation therapy, is compared to standard treatment for elderly patients with advanced head and neck cancer who cannot have chemotherapy.
Rekha Chaudhary, MD
Skin Cancer & Sarcoma
Phase 2
Protocol SN2426
This phase II trial compares amivantamab plus hyaluronidase given under the skin to cetuximab given intravenously in immunocompromised adults with recurrent or metastatic cutaneous squamous cell carcinoma. The study looks at safety and how long patients live without cancer growth, with treatment up to about 2 years and follow-up for several years.
Kerri McGovern, MD
Head and Neck Cancer
Protocol TP-CA-006
An observational study collecting tumor tissue and blood over time from adults with metastatic or unresectable head and neck squamous cell carcinoma starting first‑line anti‑PD‑1/PD‑L1 therapy. Tests will include NGS, ctDNA, RNA, and immune profiling to discover biomarkers linked to treatment response and resistance. Follow up is up to 5 years.
Kerri McGovern, MD
Head and Neck Cancer
Phase 3
Protocol 61186372HNC3001 OrigAMI-5
This study is to see how well a treatment that includes amivantamab, pembrolizumab and carboplatin works compared to a different treatment that includes 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) therapy. 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) are already used together to treat recurrent/metastatic head and neck squamous cell carcinoma.
Kerri McGovern, MD
Lung Cancer
Phase 3
Protocol ResQ201A-NSCLC
The trial compares a new therapy involving N-803 and tislelizumab with standard treatment for advanced lung cancer. It's aimed at patients whose cancer did not respond well to previous immune-based treatments. Enrolled participants will be watched over a year to determine which treatment better increases survival rates.
Kyle Wang, MD
Radiation Oncology
Protocol 2024-0002
This study uses routine radiation planning CT scans to look for signs of heart artery calcium and help identify heart disease earlier in people receiving cancer radiation therapy.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol D702BC00001 ARTEMIDE-Lung02
This study compares rilvegostomig against pembrolizumab when taken with chemotherapy for treating advanced squamous NSCLC in patients whose tumors express PD-L1.
Ian Paquette, MD
Gastrointestinal Cancer
Protocol CCTG-CO32
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Zulfa Omer, MD
Other
Protocol 10590
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor
Phase 1
Protocol TV56278-ONC-10203
This study tests the safety and effectiveness of TEV-56278, alone and with Pembrolizumab, in treating advanced solid tumors. Participants will be involved for up to two years, receiving treatment and undergoing monitoring to assess drug safety and any anti-tumor activity.
Kerri McGovern, MD
Head and Neck Cancer
Phase 3
Protocol NRG-HN016
This randomized phase 3 trial tests whether adding weekly carboplatin and paclitaxel to radiation is better than weekly cetuximab with radiation for people with advanced head and neck cancer who cannot take cisplatin. Patients receive 35 radiation treatments over about 7 weeks plus weekly drug doses, with follow-up visits for several years to measure cancer control, survival, side effects, and eating/speaking function.
Emily Curran, MD
AML/ALL
Phase 3
Protocol HOVON-177_AMLSG 35-24__BAML-16-001-S26
This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.
Bailey Nelson
Genitourinary Cancer
Phase 2
Protocol S2427
This Phase II study gives pembrolizumab with external beam radiation to patients whose muscle invasive bladder cancer has responded to pre-surgery chemotherapy. The goal is to see if this approach preserves the bladder and achieves at least 70% bladder intact event-free survival at 3 years, while tracking side effects and quality of life over up to 5 years.
Jennifer Leddon, MD, PhD
Skin Cancer & Sarcoma | Breast Cancer
Phase 1
Protocol AMXT1501-103
This Phase 1b/2 trial tests two oral agents, AMXT 1501 and DFMO, added to standard therapies in patients with advanced ER+ / HER2- breast cancer or unresectable/metastatic cutaneous melanoma. The study looks for a safe dose, records side effects, measures tumor responses, and studies drug levels and tumor changes. About 92 patients may enroll.
Trisha Wise-Draper, MD, PhD
Head and Neck Cancer
Protocol 10492
This study investigates whether adding ipatasertib to standard chemo-radiation improves treatment outcomes for head and neck cancer. The goal is to find a safe dose that might offer better cancer control than existing therapies alone.
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor | Skin Cancer & Sarcoma | Lung Cancer
Phase 1
Protocol IOV-GM1-201
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Robert Franklin, MD
Genitourinary Cancer
Protocol S1931
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic).
Jordan Kharofa, MD
Gastrointestinal Cancer
Phase 3
Protocol NRG-GI011
This study tests if higher doses of radiation therapy help people with advanced pancreatic cancer live longer after initial chemotherapy. It compares this treatment to regular care options like continued chemotherapy or observation and measures survival and quality of life impacts.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor | Gastrointestinal Cancer
Phase 1
Protocol ETCTN 10670
This study tests a new combination of cancer drugs for people with advanced colorectal cancer that hasn't responded to other treatments. It aims to find a safe dose that can be tolerated by most patients while seeing if the drug combo is effective in treating the cancer.
Emily Curran, MD
AML/ALL
Protocol A041501
This phase 3 trial tests whether adding the antibody drug inotuzumab ozogamicin to a pediatric-style chemotherapy plan is safe and helps young adults with newly diagnosed B-cell ALL stay in remission longer. Patients who respond to induction chemo are randomized to standard therapy with or without inotuzumab. The study follows patients for treatment effects, side effects, and long-term outcomes.
Tahir Latif, MD
Lymphoma
Phase 2
Protocol ALLO-501A-202
This study tests a new treatment called cema-cel for adults with large B-cell lymphoma who show minimal residual disease after initial therapy. It aims to compare this treatment's effectiveness and safety against standard observation post-treatment.
Amanda Jackson, MD
Gynecologic Cancer
Phase 3
Protocol DS8201-854/GOG-3122
This Phase 3 trial compares trastuzumab deruxtecan to standard chemotherapy (with or without radiotherapy) after surgery in people with HER2-positive Stage IIC or III endometrial cancer. It looks primarily at disease-free survival and also tracks overall survival and safety over several years.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 3
Protocol RMC-6236-303
This randomized Phase 3 study compares the oral drug daraxonrasib (RMC-6236) to standard chemotherapy in people with metastatic pancreatic ductal adenocarcinoma who have had one prior chemotherapy. The study measures whether daraxonrasib improves time without cancer progression and overall survival, with special focus on patients with RAS G12 mutations. Other measures include tumor response, quality of life, side effects, and drug levels in the blood. The study follows patients for up to about three years.
Jordan Kharofa, MD
Head and Neck Cancer
Phase 1
Protocol UCCC-HN-24-01
This trial tests short-course proton or photon radiation given with pembrolizumab before salvage surgery in recurrent head and neck squamous cell carcinoma. Phase I finds a safe radiation dose; Phase II compares the two radiation types to see if the combo increases major pathologic response. Patients are followed for safety and long-term outcomes up to 5 years.
Sara Medek, MD
Head and Neck Cancer
Phase 2
Protocol EA3132
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck and disruptive p53 mutations who have undergone surgery.
Ed Faber, MD
Lymphoma | CLL | Other
Phase 1
Protocol P-CD19CD20-ALLO1-001
This clinical trial, sponsored by Poseida Therapeutics, is an open-label, Phase 1 study evaluating the safety of P-CD19CD20-ALLO1 CAR-T cells in adults with certain relapsed or refractory B cell malignancies. The study involves dose escalation to find a safe dosage and examines the treatment's safety and effectiveness over time. Participants will undergo lymphodepletion therapy before receiving the CAR-T cells. The trial aims to measure safety, adverse events, and responses to treatment, including survival rates and progression-free survival.
Robert Franklin, MD
Phase 1 - Solid Tumor | Skin Cancer & Sarcoma | Lung Cancer | Genitourinary Cancer
Phase 1
Protocol DB-1311-O-1001
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.
Zulfa Omer, MD
Other
Protocol ETCTN 10637
This study examines whether venetoclax is effective in treating patients with relapsed hairy cell leukemia. It involves taking the medication daily and regular check-ups for up to 19 cycles.
Trisha Wise-Draper, MD, PhD
Brain Cancer
Gliomas- Letrozole+Standard Therapy
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor
Phase 2
Protocol DB-1311-201
Phase 2 open-label trial testing DB-1311 combined with BNT327 or DB-1305 in people with advanced solid tumors. The study will look at safety, side effects, how the drugs behave in the body, and early signs of tumor response over up to 6 years.
Lalanthica Yogendran, MD
Brain Cancer
Phase 2
Protocol A072201
This study compares new drugs, relatlimab and nivolumab, with traditional chemotherapy for treating recurrent glioblastoma to see which is more effective and safer.
Lalanthica Yogendran, MD
Brain Cancer
Phase 3
Protocol A072301
This randomized Phase 3 trial tests whether adding vorasidenib (an IDH inhibitor) to standard temozolomide after radiation helps people with newly diagnosed IDH‑mutant grade 3 astrocytoma live longer without tumor progression. Patients receive radiation, then are randomly given temozolomide plus vorasidenib or temozolomide plus placebo for up to 12 months, with long‑term follow up for up to 10 years.
Sarah Sittenfeld
Gynecologic Cancer
Protocol UCCC-RT-25-05
A single group study of 28 women with cervical cancer who will start pelvic floor physical therapy about 4 weeks after finishing pelvic radiation. The main goal is to find how many have fecal incontinence three months after treatment using a standard survey. Other measures include urinary symptoms, sexual symptoms, quality of life, dilator use, and pelvic floor muscle function.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Protocol S2104
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Thomas Herzog, MD
Gynecologic Cancer
Phase 3
Protocol MK-2870-022/GOG-3103
This study tests a new drug for ovarian cancer that has returned. It compares the new treatment's safety and effectiveness with standard care to see if patients live longer without their disease getting worse. Patients will be closely monitored for side effects.
Amanda Jackson, MD
Gynecologic Cancer
Phase 2
Protocol FTH-PIK-201
This study tests a combination of drugs with a special diet in patients with advanced endometrial cancer. It seeks to find out if this new treatment improves patient outcomes and understand any side effects. To join, patients must have failed previous treatments like chemotherapy. Participants must fit specific criteria, including having certain genetic markers, and they should not have other major health issues.
Anthony Faiola, PhD
Brain Cancer
Protocol UCCC-BN-25-01
The purpose of this research study is to evaluate a new virtual reality gaming system to see if it can help improve memory and concentration in brain cancer survivors with mild cognitive impairment.
Tahir Latif, MD
Lymphoma
Phase 2
Protocol EA4231
This study is testing a combination of 5 drugs-venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid-called ViPOR, to see if it is effective in treating patients with certain types of aggressive B-cell lymphoma that have come back or not responded to treatment.
Trisha Wise-Draper, MD, PhD
Head and Neck Cancer
Phase 2
Protocol NRG-CC013
This study explores if the drug BMX-001 can reduce painful mouth sores in patients undergoing chemoradiation therapy for head and neck cancer. By comparing it to a placebo, researchers aim to see if BMX-001 offers additional relief.
Alberto Martini, MD
Urology | Genitourinary Cancer
Phase 3
Protocol UT002
This study tests how well a new drug, UGN-104, treats low-grade upper tract urothelial cancer. Participants receive weekly doses for 6 weeks, followed by possible monthly maintenance doses if they respond well. Participants are monitored for safety and effectiveness over about 15 months.
Alberto Martini, MD
Urology | Genitourinary Cancer
Phase 2
Protocol CORE-008
This Phase 2 trial tests cretostimogene given into the bladder for people with high risk non muscle invasive bladder cancer. It includes groups who are BCG naive, previously treated with BCG, or BCG unresponsive. One group also tests adding gemcitabine. Main goals are tumor response, time free of high grade events, and safety. Treatment begins with 6 weekly doses and continues with scheduled maintenance and long term checks.
Adam Rojan, MD
Gastrointestinal Cancer
Protocol NRG-GI008
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Chad Zender, MD
Head and Neck Cancer
Phase 2
Protocol 10706
This randomized phase 2 trial tests whether adding the anti‑CD40 antibody CDX‑1140 to cemiplimab before surgery improves the amount of tumor killed in adults with stage III–IV head and neck cancer. The study also evaluates safety and biomarkers and follows patients for about two years after surgery.
Ed Faber, MD
Myeloma
Phase 3
Protocol 64007957MMY3005
This study tests new medication combos, teclistamab and talquetamab, for treating newly diagnosed multiple myeloma patients who can't have a stem cell transplant yet. It compares their effectiveness against current standard treatments over several years.
Robert Franklin, MD
Genitourinary Cancer
Phase 3
Protocol A032103
This study is testing if a blood test that checks for DNA from bladder cancer cells can guide the use of immunotherapy after surgery. It aims to find out if this approach can help prevent the cancer from coming back. The study will involve patients who have had bladder cancer surgery and will look at how well additional treatments work based on the blood test results.
Robert Franklin, MD
Phase 1 - Solid Tumor
Phase 1
Protocol JZP898-101
This study tests a new drug JZP898, alone and with pembrolizumab, in adults with advanced solid tumors. Researchers are checking its safety and effects on tumors.
Ed Faber, MD
Myeloma
Phase 1
Protocol M24-108
This study tests ABBV-383, a drug for relapsed/refractory multiple myeloma, focusing on safety and side effects. About 180 people will participate globally, receiving the drug by IV every 28 days for up to three years, with regular check-ups.
Kerri McGovern, MD
Breast Cancer
Protocol TP-CA-010
This study uses blood tests to look for tiny bits of tumor DNA (ctDNA) over time in people treated for breast cancer. It aims to see if ctDNA can predict cancer return and measure treatment response during up to five years of follow-up.
Davendra Sohal, MD, MPH
Head and Neck Cancer
Phase 2
Protocol BNT113-01
This study looks into a new treatment approach using BNT113 and pembrolizumab for head and neck cancer linked to HPV16. Patients' safety, response rates, and overall survival will be compared between those getting the combined treatment versus standard pembrolizumab treatment alone.
Zulfa Omer, MD
CLL
Phase 1
Protocol ZE50-0134-0002
This study tests ZE50-0134 in adults with certain blood cancers like chronic lymphocytic leukemia that have not responded to standard treatments. Researchers aim to find a safe dose level and evaluate effectiveness over several weeks through different stages of testing. Participants should not have certain serious health conditions.
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor
Phase 1
Protocol PYX-201-101
This study is testing PYX-201, a new drug for patients with advanced solid tumors that didn't respond to traditional treatments. Researchers want to determine the safest dose while checking for any side effects.
Amanda Jackson, MD
Gynecologic Cancer
Protocol NRG-CC008
The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor | Gastrointestinal Cancer
Protocol 10522
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing.
Adam Rojan, MD
Gastrointestinal Cancer
Phase 3
Protocol SMT112-3005 (HARMONi-GI3)
A phase 3, randomized, active-controlled, double-blind, multiregional study comparing Ivonescimab in combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in combination with mFOLFOX6 in patients with metastatic colorectal cancer who have not previously received systemic therapy for metastatic disease.
Jennifer Leddon, MD, PhD
Head and Neck Cancer
Phase 2
Protocol BCA101X301
This clinical trial is testing a new drug combination, ficerafusp alfa and pembrolizumab, to treat certain head and neck cancers. Participants will either receive the new combination or a placebo, and researchers aim to assess its safety and effectiveness over several years.
Emily Curran, MD
AML/ALL
Phase 1
Protocol BAML-16-001-S24
This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.
Emily Curran, MD
Principal Investigator
AML/ALL
Phase 1
Protocol BAML-16-001
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Thomas Herzog, MD
Gynecologic Cancer
Phase 3
Protocol MK2870-021/GOG-3102
This Phase 3 trial tests sacituzumab tirumotecan (with or without bevacizumab) as maintenance treatment after surgery and first-line chemotherapy for newly diagnosed HRD-negative advanced ovarian cancer. The main goal is to see if this approach delays cancer progression compared to standard care, while monitoring safety and quality of life over several years.
Emily Curran, MD
AML/ALL | Blood Cancer
Protocol ETCTN 10596
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene.
Leeya Pinder, MD, PhD
Cancer Screening & Prevention
Protocol LMI-001-A-S04
This study compares self-collected vaginal HPV tests to clinician-collected cervical tests in adults referred for colposcopy after abnormal screening. It checks how well self-collection detects high-risk HPV and cervical precancer, and asks about ease of use and preferences. Outcomes are measured from one visit with lab results within 60 days.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor | Gastrointestinal Cancer
Protocol 10579
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment.
Robert Franklin, MD
Genitourinary Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body.
Olugbenga Olowokure, MD
Gastrointestinal Cancer
Phase 3
Protocol S2433
This randomized phase III trial tests whether adding panitumumab to standard second line chemotherapy improves survival for adults with unresectable or metastatic KRAS wild type pancreatic cancer. Participants receive chemotherapy with or without panitumumab until progression or unacceptable side effects, with follow up for up to three years. The study also looks at tumor response, side effects, and quality of life.
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor | Skin Cancer & Sarcoma
Phase 1
Protocol IDE196-001
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.
Kerri McGovern, MD
CML | MDS/MPN | CLL | Head and Neck Cancer | Skin Cancer & Sarcoma | Lung Cancer | Breast Cancer | Brain Cancer | AML/ALL | Lymphoma | Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer | Myeloma
Phase 3
Protocol A211901
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Emily Curran, MD
AML/ALL
Phase 1
Protocol 10630
This study tests if a combination of three drugs can safely treat newly diagnosed AML patients. Researchers seek to find the safest dose and see how well this drug combo helps fight leukemia.
Ed Faber, MD
Blood Cancer | Myeloma
Phase 1
Protocol P-BCMA-ALLO1-001
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Tahir Latif, MD
Lymphoma | Blood Cancer
Phase 1
Protocol LYL314-101
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.
Zulfa Omer, MD
CLL
Phase 2
Protocol NX-5948-201
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Ed Faber, MD
Myeloma
Phase 2
Protocol LPS18183
This study looks at a new treatment combination for people with multiple myeloma not responding to previous treatments. Using isatuximab, carfilzomib, and dexamethasone, it aims to find out if this combo is effective and how it affects patients.
Zulfa Omer, MD
Lymphoma | CLL | Other
Phase 1
Protocol NX-5948-301
This Phase 1 study tests NX-5948, an oral BTK degrader, in adults with relapsed or refractory B‑cell cancers. The study will find safe dose(s), track side effects and drug levels, and see if the drug can shrink or control these cancers across several disease groups.
Kerri McGovern, MD
Breast Cancer
Phase 3
Protocol A012303
This trial compares 6 months versus 12 months of HER2-targeted therapy (trastuzumab with or without pertuzumab) in people with early HER2-positive breast cancer who had no invasive cancer at surgery after pre-surgery chemo. It checks cancer recurrence, quality of life, side effects, and long-term outcomes with up to 10 years follow-up.
Eric Vick, MD
Phase 1 - Hematologic Malignancies
Phase 1
Protocol AJX-101
This study tests the safety and effectiveness of a new drug, AJ1-11095, on myelofibrosis patients who haven't responded to previous treatments. Participants will receive the drug to find out the safest dose.
Jennifer Leddon, MD, PhD
Phase 1 - Solid Tumor | Skin Cancer & Sarcoma
Phase 1
Protocol GIM531-CT01
This study is testing a new drug called GIM-531 for people with advanced solid tumors. They want to know if it's safe and works well, especially for those who haven't responded to other treatments. Participants must have advanced cancer and cannot have certain medical conditions.
Chad Zender, MD
Head and Neck Cancer | Skin Cancer & Sarcoma
Phase 3
Protocol NRG-HN014
This study evaluates whether adding the immunotherapy drug cemiplimab to surgery improves treatment outcomes for patients with advanced, resectable skin cancer.
Sara Medek, MD
Head and Neck Cancer
Phase 4
Protocol CHS-007-01 / RTOG 3521
This study tests if a drug combo, including toripalimab, helps treat certain advanced nasopharyngeal cancers. Participants should not have had similar treatments before or foreign growths that are curable with other treatments. Researchers will assess benefits like tumor shrinkage.
Zulfa Omer, MD
Lymphoma | CLL
Protocol NX-5948-301
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol 22615 SOHO-02
This study tests BAY 2927088 for treating advanced lung cancer with HER2 mutations, comparing it to current treatments. It focuses on safety and effectiveness through various health checks and scans over up to four years.
Bailey Nelson
Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer
Protocol UCCC-RT-25-02
This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.
Jordan Kharofa, MD
Gastrointestinal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer.
Timothy Struve, MD
Genitourinary Cancer
Phase 2
Protocol NRG-GU012
The study looks at whether adding stereotactic radiation to immunotherapy helps patients with advanced kidney cancer that can't be removed by surgery. The study aims to improve how well treatments work together against cancer progression.
Zulfa Omer, MD
Lymphoma | CLL
Phase 1
Protocol UB-VV111-01
This study tests a new treatment, UB-VV111, with or without Rapamycin in patients with certain returning B-cell cancers. It evaluates the safety and how well the treatment works over two years. Eligible participants must meet specific health criteria. Pregnant women and people with certain conditions cannot join.
Thomas Herzog, MD
Gynecologic Cancer
Phase 3
Protocol GCT1184-03/ GOG-3128/ENGOT-en31
A Phase 3 randomized trial of Rina S versus investigator choice chemotherapy (paclitaxel or doxorubicin) in about 544 people with recurrent or progressive endometrial cancer after prior platinum chemotherapy and PD(L)-1 therapy. Main goals are to compare progression free survival and overall survival, plus response, safety, and quality of life. Study is open label and lasts about 3 years.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor
Phase 1
Protocol J5J-OX-JZZA
This study examines the safety and effectiveness of the drug LY3962673 for treating cancers with the KRAS G12D mutation. This includes certain types of pancreatic, lung, and colon cancers. The study will explore how well the drug works alone and alongside other treatments over a period of five years.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor
Phase 1
Protocol YL211-INT-101-01
This study investigates a new drug, YL211, to assess its safety and effectiveness in treating patients with advanced solid tumors. The goal is to determine optimal dosing and observe any side effects over about three years.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 2
Protocol GO44479
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor
Phase 1
Protocol C5421001
This study tests a new cancer drug, PF-07934040, for people with advanced tumors having KRAS mutations. Participants will take this drug alone or with other therapies to see its safety and effectiveness. The study lasts up to four years, with regular clinic visits.
Ed Faber, MD
Myeloma
Phase 3
Protocol EMN30/64007957MMY3003
A Phase 3 randomized trial testing whether teclistamab, alone or with lenalidomide, is a better maintenance treatment after transplant than lenalidomide alone in people with newly diagnosed multiple myeloma. Main goals are longer time without disease worsening and more patients having no detectable disease at 12 months.
Jordan Kharofa, MD
Cancer Screening & Prevention
Protocol A212101
This trial compares two ways to notify family members about inherited cancer risk after a new colorectal cancer diagnosis: the patient tells relatives, or healthcare providers contact them directly. It measures which approach leads to more relatives getting genetic testing and taking recommended prevention steps.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 1
Protocol DB-1324-101
This first-in-human Phase 1/2 trial tests DB-1324, an antibody-drug conjugate, in people with advanced GI cancers. The main goals are to find a safe dose, learn how the drug acts in the body, and see early signs it can shrink tumors. Participants receive treatment until progression, unacceptable side effects, or withdrawal.
Amanda Jackson, MD
Gynecologic Cancer
Phase 1
Protocol M25-219/GOG-3124
This Phase 1b trial studies the safety and early effectiveness of IMGN151 given alone or with carboplatin, olaparib, or bevacizumab in adults with gynecologic cancers. About 377 participants will be treated over about 3 years and will have regular clinic visits, tests, and scans.
Zulfa Omer, MD
CLL
Phase 2
Protocol UCCC-HEM-24-01
Epcoritamab as consolidation therapy
Alberto Martini, MD
Urology | Genitourinary Cancer
Phase 2
Protocol MVR-T3011-006
This clinical study is testing a Herpes Virus injection for bladder cancer that hasn't responded to standard treatments. The study seeks to determine if this new treatment is safe and effective by administering two different dosages. Researchers aim to see improvements in patient outcomes over visits spanning up to two years.
Sara Medek, MD
Head and Neck Cancer
Protocol UCCC-RT-25-03 (REDUCE-30)
The purpose of this research is to study if a decrease in the dose of radiation to regions which have no visible cancer will be as effective as the standard dose. The dose to all visible cancer remains unchanged to the standard radiation approach. The researchers believe that a lower dose could be just as helpful for treating your cancer, while reducing the side effects of radiation and improving quality of life.
Zulfa Omer, MD
CLL
Phase 2
Protocol UCCC-HEM-24-02
This is a multicenter parallel two cohort, phase II clinical trial designed to evaluate the combination of obinutuzumab + LP-168 for the treatment of: 1) previously treated, and 2) BTK T474I ( gate keeper mutation) mutated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients.
Davendra Sohal, MD, MPH
Lymphoma | Phase 1 - Solid Tumor | Myeloma
Phase 2
Protocol TAPUR
This study explores how FDA-approved drugs targeting specific tumor gene abnormalities affect patients with certain advanced cancers. Eligible participants should be 12 years and older and meet specific inclusion criteria.
Jamie Lewis, MD
Breast Cancer
Protocol NRG-CC015
This study investigates if digital mindfulness methods help younger women who survived breast cancer manage depression. It compares a live online program to a self-paced app to find the best solution for improving mental health.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol MK-1084-004
This study explores the combination of MK-1084 and pembrolizumab for treating a specific type of lung cancer. It checks if this duo is better than current options by increasing survival rates and slowing cancer progression.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol NVL-655-04
This Phase 3 trial enrolls people with untreated ALK-positive advanced non-small cell lung cancer. It compares neladalkib (NVL-655) with alectinib to see which drug better delays cancer progression. About 450 patients will be randomized and followed for up to five years for cancer outcomes, brain effects, safety, and quality of life.
Emily Curran, MD
AML/ALL
Phase 3
Protocol BAML-16-001-S25
This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.
Alberto Martini, MD
Urology | Genitourinary Cancer
Phase 3
Protocol ABLE-32 (000423)
The study compares a new treatment called Nadofaragene Firadenovec with regular observation in people who have a specific type of bladder cancer. The key focus is on preventing the cancer from returning or getting worse.
Emily Curran, MD
AML/ALL
Phase 2
Protocol BAML-16-001-S21
This master trial screens AML patients with fast genomic and lab testing and assigns them to one of several targeted treatment sub-studies. The main goals are to show testing and assignment can be done within 7 days and to evaluate treatment response and safety over time.
Kerri McGovern, MD
Head and Neck Cancer
Phase 2
Protocol NRG-HN010
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable).
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol V940-009
This study is examining if adding the drug V940 to pembrolizumab helps prevent non-small cell lung cancer from returning after surgery. Participants must meet specific health criteria and cannot have certain prior treatments or conditions. The research will assess various health outcomes like survival and quality of life over a period that could last up to about 129 months.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Protocol 10608
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable).
Alberto Martini, MD
Urology | Genitourinary Cancer
Phase 2
Protocol ABLE-22 (000434)
This study explores new treatment options for high-grade non-muscle invasive bladder cancer using a drug called nadofaragene firadenovec. Participants receive this treatment alone or combined with chemotherapy or immunotherapy to measure its effectiveness in reducing cancer recurrence.
Robert Franklin, MD
Genitourinary Cancer
Phase 3
Protocol 78278343PCR3003
This randomized phase 3 trial compares pasritamig plus docetaxel to docetaxel alone in men with metastatic castration resistant prostate cancer to see if the combination delays radiographic disease progression and affects survival, symptoms, quality of life, and side effects.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor
Phase 1
Protocol TTX-080-001
TTX-080 monotherapy (HLA-G inhibitor) +/- pembrolizumab or cetuximab
Tahir Latif, MD
Lymphoma
Phase 2
Protocol MK2140-011
A phase 2 trial comparing zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP in people with newly diagnosed GCB subtype DLBCL. The main goal is to see which treatment gives more complete responses at the end of therapy and to compare safety and longer term outcomes.
Zulfa Omer, MD
CLL
Phase 2
Protocol UCCC-HEM-23-01
Venetoclax therapy with Acalabrutinib
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 1
Protocol ETCTN 10629
Researchers are studying whether adding a new drug, iadademstat, to existing immunotherapies can better control small cell lung cancer. The study involves repeated cycles of treatment and aims to find out if this combination can keep the cancer stable longer than current treatments alone.
Robert Franklin, MD
Genitourinary Cancer
Phase 3
Protocol 78278343PCR3001 (KLK2-ComPAS)
A phase 3 randomized trial testing pasritamig, a T cell redirecting drug, plus best supportive care versus placebo plus best supportive care in people with metastatic prostate cancer that no longer responds to hormones. The main goal is to see if pasritamig improves overall survival. The study also tracks disease progression, pain, quality of life, and safety over about 2 years and 8 months.
Sarah Sittenfeld
Gynecologic Cancer
Phase 3
Protocol NRG-GY037
This Phase 3 trial tested whether adding targeted hemithoracic radiation (IMPRINT) after pleurectomy/decortication and standard chemotherapy improves survival for stage I-IIIA malignant pleural mesothelioma. It also looked at local control, spread, side effects, and quality of life. The trial closed early, so only limited results were available.
Davendra Sohal, MD, MPH
Phase 1 - Solid Tumor
Phase 1
Protocol YL217-INT-101-01
This study examines how a new cancer drug, YL217, works on patients with advanced solid tumors. Patients must be adults with measurable tumors and good health status. Researchers want to learn about the drug's safety and effectiveness.
Andrew Frankart, MD
Head and Neck Cancer | Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer
Protocol UCCC-RT-23-01
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 3
Protocol CA224-1093
This study compares two drug combinations for treating advanced lung cancer. It aims to see which treatment helps patients live longer and whether they can manage side effects.
Robert Franklin, MD
Genitourinary Cancer
Phase 1
Protocol XmAb819-01
This study is exploring the safety and proper dose of a new drug, XmAb819, for treating a type of kidney cancer that hasn't responded to other treatments. Participants will get the drug either by IV or injection and be closely monitored for side effects and changes in their cancer.
Emily Curran, MD
Cancer Screening & Prevention
Protocol TP-CA-009
A non-interventional study collecting blood, tissue, and bone marrow samples from people with AML or follicular lymphoma over time. Molecular analyses will be linked to real-world outcomes to find markers that may guide treatment and predict prognosis. Follow-up is up to 5 years.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 2
Protocol BNT327-06
This study is testing a new drug called BNT327 with chemotherapy in adults with a type of lung cancer known as non-small cell lung cancer. It's looking at whether this treatment combo can help patients live longer and experience fewer tumor growths. The study involves regular visits over a period of up to 5 years.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 2
Protocol CORT125134-558 (TRIDENT)
This Phase 2 trial tests relacorilant given with nab-paclitaxel and gemcitabine for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma. It looks at how long patients live without cancer growth, overall survival, tumor response, blood tumor marker changes, safety, and drug levels. Treatment is given in 28-day cycles until disease progression or unacceptable toxicity.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 1
Protocol DISP-10-101
Phase 1 study testing DISP 10 (an adenovirus plus CAR T therapy) in adults with advanced esophageal, stomach, gastroesophageal junction, or colorectal cancers. The trial will find a safe dose, check side effects, and see if tumors respond. Participants need measurable disease and good organ function.
Leeya Pinder, MD, PhD
Gynecologic Cancer
Protocol EASTER P2
This study will develop and test an affordable AI system that screens for high‑risk HPV in urine and uses AI‑read cervical images to find cervical precancer and guide treatment. It will enroll about 3,200 women in Zimbabwe, compare the new tests to standard HPV testing and biopsy results, and assess costs and accuracy.
Emily Curran, MD
CML | MDS/MPN | Lymphoma | AML/ALL | CLL | Blood Cancer | Myeloma | Other
Phase 1
Protocol LP-118-US-I01
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Kerri McGovern, MD
Breast Cancer
Protocol A012103
Pembro or Observation
Caroline Billingsley, MD
Gynecologic Cancer
Phase 3
Protocol GOG-3068
This study investigates whether heated chemotherapy applied during surgery, followed by the drug niraparib, improves outcomes for patients with advanced ovarian, primary peritoneal, and fallopian tube cancers. Two groups will be compared: one receiving heated chemotherapy and the other not. All patients will receive standard chemotherapy and then niraparib after surgery.
Jennifer Leddon, MD, PhD
Lung Cancer
Phase 2
Protocol IOV-LUN-202
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Caroline Billingsley, MD
Gynecologic Cancer
Phase 1
Protocol ACR-368-201
This open-label Phase 2 trial studies ACR-368 alone or with ultra-low dose gemcitabine in people with high-grade endometrial cancer. Patients are grouped by a predictive test when available. The study measures tumor response every 8 weeks and monitors safety and survival for up to 2 years.
Tahir Latif, MD
Lymphoma
Phase 3
Protocol LYL314-102
This randomized Phase 3 trial compares ronde‑cel, a dual CD19/CD20 CAR T therapy, with approved CD19 CAR T options in people with relapsed or refractory large B‑cell lymphoma after first‑line treatment. About 400 patients will receive one CAR T infusion after short chemo, and will be followed for 3 years to compare event‑free survival, responses, survival, and safety.
Robert Franklin, MD
Phase 1 - Solid Tumor | Genitourinary Cancer
Phase 1
Protocol LOXO-FG3-22001
This study is looking at how effective and safe LOXO-435 is for treating specific advanced cancers. Participants will have cancers with a particular gene change (FGFR3) and will be observed over about 2.5 years.
Davendra Sohal, MD, MPH
Gastrointestinal Cancer
Phase 1
Protocol RMC-GI-102
This study evaluates new RAS inhibitors combined with standard or new treatments for patients with gastrointestinal cancers, including colorectal and pancreatic cancers. The focus is on safety, tolerability, and early antitumor effects. The study has three parts, each testing different drug combinations. Participants must be adults with certain cancer types and meet health criteria. Outcomes include monitoring adverse events, drug levels, and patient responses over time.
Bailey Nelson
Radiation Oncology
Protocol 2016-1287
This study tests whether a short educational video helps people better understand radiation treatment and the consent process.
Leeya Pinder, MD, PhD
Gynecologic Cancer | Cancer Screening & Prevention
Protocol IMPACT-513
This program offers HPV self-testing through a mobile clinic to improve access to cervical cancer screening.
Robert Franklin, MD
Genitourinary Cancer
Phase 1
Protocol PSMA-007-001
This study is testing a new drug, JANX007, for treating advanced prostate cancer that has spread and is resistant to other treatments. It aims to determine the safety of the drug and how patients handle its side effects.
Emily Curran, MD
AML/ALL
Phase 2
Protocol 21CTP.LEUK01
This phase II trial adds asciminib to dasatinib, prednisone, and blinatumomab for adults with newly diagnosed Ph+ CD19+ acute lymphoblastic leukemia. The study checks whether this combination improves deep molecular remission by about day 85 and monitors remission, survival, and side effects. Treatment includes induction, consolidation cycles, and long-term maintenance up to five years.